מניית אדוארדס מזנקת לאחר ש‑CMS מציעה להרחיב את הכיסוי ל‑TAVR

מניית אדוארדס מזנקת לאחר ש‑CMS מציעה להרחיב את הכיסוי ל‑TAVR

דה פליי (TheFly)16 ביוני 2026

The Centers for Medicare and Medicaid Services released a national coverage analysis, proposing to cover transcatheter aortic valve replacement for symptomatic severe aortic valve stenosis without the coverage with evidence development requirement, expand coverage of TAVR to asymptomatic severe aortic stenosis, and revise coverage criteria related to pre-procedural patient assessment, intraoperative requirements, and operator and hospital procedural volume requirements. The CMS proposed that TAVR for severe aortic stenosis is covered when furnished with a complete aortic valve and implantation system that has received Food and Drug Administration premarket approval for that system’s FDA-approved indication. Shares of Edwards Lifesciences (EW) are up 3% to $89.23 in premarket trading.